30 Participants NeededMy employer runs this trial

Panitumumab-IRDye800 for Brain Cancer

MB
NJ
Overseen ByNicole Jones
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: Eben Rosenthal
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.

Who Is on the Research Team?

PM

Peter Morone, MD

Principal Investigator

Vanderbilt University Medical Center

Are You a Good Fit for This Trial?

This trial is for adults (18+) with brain tumors or lesions who are scheduled for surgical removal. Participants must have normal blood tests, not be pregnant if female, and be able to give consent themselves or through a healthcare decision maker.

Inclusion Criteria

I am 18 years old or older.
Women of childbearing potential must have a negative pregnancy test within 7 days of study drug administration
I am able and willing to sign a consent form for this study.
See 2 more

Exclusion Criteria

Baseline QTcF interval greater than 480 milliseconds
I am currently pregnant or breastfeeding.
I have had lung scarring or inflammation in the past.
See 5 more

What Are the Treatments Tested in This Trial?

Interventions

  • Panitumumab-IRDye800

Trial Overview

The study is testing Panitumumab-IRDye800, a fluorescent imaging agent that targets EGFR, to see how well it helps surgeons detect brain tumors during surgery. The main focus is on safety and how clearly the dye highlights tumor tissue.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Study Arm - 50 mg pan800Experimental Treatment1 Intervention
Group II: Study Arm - 100 mg pan800Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Eben Rosenthal

Lead Sponsor

Trials
9
Recruited
200+